No link yet. Here's the text:
[CTIX} is pleased to announce that the clinical database for the Phase 2 clinical trial of Prurisol for the treatment of mild to moderate chronic plaque psoriasis is expected to be "unblinded" next week. Once the blind is removed, data from each of the four arms of the trial (one placebo arm, three oral dosing regimens of Prurisol) will be reviewed and analyzed to evaluate the safety and efficacy of Prurisol. CTIX expects to release top-line data from the study approximately one week after the blind is removed.
Separately in CTIX's dermatology pipeline, the Company last month reactivated a request for a Pre-IND (Investigational New Drug) meeting with the U.S. FDA to discuss initiating clinical research of Brilacidin, CTIS's lead defensin mimetic, for the treatment of the inflammatory skin condition hidradenitis suppurativa. CTIX previously filed the request, ultimately electing to hold off on clinical studies of Brilacidin for dermatological uses until several other clinical trials sponsored by the Company were complete or neared completion. CTIX ianticipates the meeting to transpire in June 2016 and will be submitting a Briefing Book to the FDA on the planned trial one month prior to the meeting.
[CTIX} is pleased to announce that the clinical database for the Phase 2 clinical trial of Prurisol for the treatment of mild to moderate chronic plaque psoriasis is expected to be "unblinded" next week. Once the blind is removed, data from each of the four arms of the trial (one placebo arm, three oral dosing regimens of Prurisol) will be reviewed and analyzed to evaluate the safety and efficacy of Prurisol. CTIX expects to release top-line data from the study approximately one week after the blind is removed.
Separately in CTIX's dermatology pipeline, the Company last month reactivated a request for a Pre-IND (Investigational New Drug) meeting with the U.S. FDA to discuss initiating clinical research of Brilacidin, CTIS's lead defensin mimetic, for the treatment of the inflammatory skin condition hidradenitis suppurativa. CTIX previously filed the request, ultimately electing to hold off on clinical studies of Brilacidin for dermatological uses until several other clinical trials sponsored by the Company were complete or neared completion. CTIX ianticipates the meeting to transpire in June 2016 and will be submitting a Briefing Book to the FDA on the planned trial one month prior to the meeting.
1
